Published in Gynecol Oncol on November 06, 2010
Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics (2012) 1.35
Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04
DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer (2011) 0.99
DNA methylation as clinically useful biomarkers-light at the end of the tunnel. Pharmaceuticals (Basel) (2012) 0.99
Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer (2013) 0.93
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia (2012) 0.88
Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. Int J Mol Sci (2012) 0.87
The MethDet: a technology for biomarker development. Expert Rev Mol Diagn (2011) 0.82
NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer. Int J Mol Sci (2012) 0.82
Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients. Epigenetics (2014) 0.82
Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci (2013) 0.81
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med (2017) 0.78
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. J Cancer (2016) 0.78
Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. Front Mol Biosci (2016) 0.78
CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome Biol (2017) 0.76
Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther (2016) 0.75
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
CGPredictor: a systematic integrated analytic tool for mining and examining genome-scale cancer independent prognostic epigenetic marker panels. BMC Syst Biol (2013) 0.75
RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget (2017) 0.75
Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett (2016) 0.75
Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. Int J Clin Oncol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Cancer of the ovary. N Engl J Med (1993) 4.53
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med (2001) 3.24
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell (2003) 2.31
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res (2000) 1.83
Early detection of ovarian cancer. Dis Markers (2007) 1.77
DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol (2008) 1.69
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed (2005) 1.58
Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol (2003) 1.48
Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound. Menopause (2009) 1.42
Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol (2010) 1.26
Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer (2001) 1.20
The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene (2003) 1.15
Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer (2010) 1.14
CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer (2003) 1.08
Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn (2007) 1.07
Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn (2008) 1.02
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet (2005) 1.01
A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. Genomics (1997) 1.00
BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treat Rev (2001) 1.00
The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol (2002) 0.97
Differences in symptoms between patients with benign and malignant ovarian neoplasms. Am J Obstet Gynecol (2004) 0.96
Ultrasound and assessment of ovarian cancer risk. AJR Am J Roentgenol (2010) 0.93
Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res (2003) 0.92
Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer (2009) 0.91
Management of the adnexal mass in the 1990s. South Med J (1997) 0.88
Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation. Cancer (1993) 0.84
p21(WAF1) negatively regulates DNMT1 expression in mammalian cells. Biochem Biophys Res Commun (2009) 0.83
Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer (2007) 0.83
Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer. Environ Mol Mutagen (2005) 0.80
Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Eur J Gynaecol Oncol (2009) 0.78
Ovarian cancer: challenges of early detection. Nat Clin Pract Oncol (2007) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Electric-field control of local ferromagnetism using a magnetoelectric multiferroic. Nat Mater (2008) 7.23
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med (2009) 3.80
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med (2008) 2.51
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Syphilis among female sex workers in southwestern China: potential for HIV transmission. Sex Transm Dis (2006) 2.34
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog (2006) 2.12
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 2.03
Global public health implications of a mass gathering in Mecca, Saudi Arabia during the midst of an influenza pandemic. J Travel Med (2010) 2.00
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol (2002) 1.96
Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care (2003) 1.93
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol (2011) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation (2002) 1.65
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J (2005) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun (2010) 1.61
Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol (2005) 1.61
Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 1.61
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Glucose as a prognostic factor in ovarian carcinoma. Cancer (2009) 1.59
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther (2006) 1.57
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol (2008) 1.57
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
Risk factors, hospital management and outcomes after acute myocardial infarction in South Asian Canadians and matched control subjects. CMAJ (2002) 1.57
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008) 1.56
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res (2007) 1.53